Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD

American Journal of Kidney Diseases

Volumn 60, Issue 3, 2012, Pages 371-379

  Aspinall, Sherrie L ^a,b,c   Cunningham, Francesca E ^a   Zhao, Xinhua ^b   Boresi, Joy S ^b   Tonnu Mihara, Ivy Q ^d   Smith, Kenneth J ^c   Stone, Roslyn A ^b,e   Good, Chester B ^a,b,c,f  

^a Veterans Affairs Center for Medication Safety   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

anemia; Chronic kidney disease; erythropoietin

Indexed keywords

ANTIHYPERTENSIVE AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DIALYSIS; DRUG MONITORING; FEMALE; HEALTH CARE PERSONNEL; HEART FAILURE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT CARE; PHARMACIST; PHYSICIAN; PRESCRIPTION; VETERAN;

AGED; AMBULATORY CARE; AMBULATORY CARE FACILITIES; ANEMIA; COHORT STUDIES; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HOSPITALS, VETERANS; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; ODDS RATIO; PHARMACISTS; PROFESSIONAL COMPETENCE; PROGNOSIS; QUALITY CONTROL; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865689295     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.04.013     Document Type: Article

References (25)

1. M.A. Pfeffer, E.A. Burdmann, C.-Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
2. T.B. Drueke, F. Locatelli, N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 20 2006 2071 2084
3. A.K. Singh, L. Szczech, K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 20 2006 2085 2098
4. K. Kalantar-Zadeh, G.R. Aronoff Hemoglobin variability in anemia of chronic kidney disease J Am Soc Nephrol 20 3 2009 479 487
5. I.D. Bucaloiu, G. Akers, M.C. Bernudez Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits Manag Care Interface 20 6 2007 26 30
6. S.E. Clapp, J.A. Bardo, M.M. Chrymko Implementation of a pharmacist-managed clinic for patients receiving erythropoietin-stimulating agents Am J Health-Syst Pharm 65 15 2008 1458 1463
7. C. Gilmartin Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits Am J Health-Syst Pharm 64 13 2007 S15 S22 (suppl 8)
8. J.A. Gilreath, D.S. Sageser, J.A. Jorgenson, G.M. Rodgers Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients J Natl Compr Canc Netw 6 6 2008 577 584
9. M.S. Joy, C. Candiani, B.A. Vaillancourt, H. Chin, S.L. Hogan, R.J. Falk Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease Pharmacotherapy 27 5 2007 734 744
10. T. Kimura, M. Arai, H. Masuda, A. Kawabata Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan Biol Pharm Bull 27 11 2004 1831 1833
11. L.L. To, C.P. Stoner, S.N. Stolley, J.D. Buenviaje, T.W. Ziegler Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit Am J Health-Syst Pharm 58 21 2000 2061 2065
12. G. Stemer, R. Lemens-Gruber Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review BMC Nephrol 12 2011 35 47
13. T. Walton, K.P. Holloway, M.D. Knauss Pharmacist-managed anemia program in an outpatient hemodialysis population Hospital Pharmacy 40 12 2005 1051 1056
14. Alert. 11/8/2007 Food and Drug Administration (FDA) Information for healthcare professionals: erythropoiesis stimulating agents http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm126481.htm Accessed June 17, 2011
15. National Kidney Foundation KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target Am J Kidney Dis 50 3 2007 471 530
16. A.K. Singh What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens 19 5 2010 420 424
17. National Kidney Foundation DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease Am J Kidney Dis 47 suppl 3 2006 S1 S145
18. S. Fishbane, A. Besarab Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets Clin J Am Soc Nephrol 2 6 2007 1274 1282
19. S.D. Solomon, H. Uno, E.F. Lewis Erythropoietic response and outcomes in kidney disease and type 2 diabetes N Engl J Med 363 12 2010 1146 1155
20. S.C. Palmer, S.D. Navaneethan, J.C. Craig Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease Ann Intern Med 153 1 2010 23 33
21. Alert. 11/16/2006 Food and Drug Administration (FDA) Information for healthcare professionals: erythropoiesis stimulating agents http://www.mtppi. org/fda-adv.pdf Accessed June 17, 2011
22. S. Fishbane The role of erythropoiesis-stimulating agents in the treatment of anemia Am J Manag Care 16 2010 S67 S73
23. W. Yang, R.K. Israni, S.M. Brunelli, M.M. Joffe, S. Fishbane, H.I. Feldman Hemoglobin variability and mortality in ESRD J Am Soc Nephrol 18 12 2007 3164 3170
24. L. DeNicola, G. Conte, P. Chiodini Stability of hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease Clin J Am Soc Nephrol 2 5 2007 938 946
25. J.P. Ebben, D.T. Gilbertson, R.N. Foley, A.J. Collins Hemoglobin level variability: association with comorbidity, intercurrent events, and hospitalizations Clin J Am Soci Nephrol 1 6 2006 1205 1210